The use of prostate specific antigen (PSA) in the 1990s has brought on a stage migration of prostate cancer. Despite that, many men have still presented with metastatic prostate cancer in the past decade. The use of primary hormone therapy in the PSA era at a tertiary care Army Medical Center is studied in this paper. Charts were reviewed of 135 men who were diagnosed with metastatic prostate cancer and treated with hormone therapy as a primary treatment between 1989 and 1995. Statistical analysis was used to determine significant predictor variables on the time to disease progression. In univariate analysis clinical stage, pretreatment alkaline phosphatase and nadir PSA values were significant predictors of time to progression. Race and type of treatment were not. In multivariate analysis the relative risk of progression was 3.2 for patients with an alkaline phosphatase > 252 and 16.5 for patients with a nadir > 2.0. This study supports the argument that racial disparities in prostate cancer outcomes are due to access to care. Furthermore, the survival rate for patients with D-2 disease is better than in the pre PSA studies. Clinical stage, pretreatment alkaline phosphatase and PSA nadir can be used to predict response for those men presenting with metastatic prostate cancer.
Introduction
There was an estimated 198 100 new prostate cancer cases in the USA in 2001 and 31 500 were projected to die from the disease that year. This accounts for 31% of all estimated new cancer cases and 11% of cancer deaths in men. Prostate cancer is second only to lung cancer in the number of deaths it causes in men. 1 With the advent of prostate specific antigen (PSA), PSA screening programs and increased awareness of this disease, there has been a rather dramatic stage migration to earlier stage disease, with fewer men presenting with advanced disease. 2 Specifically, at our center, approximately 20% of newly diagnosed patients had stage D disease (T1-4, N1 or M1) in the late 1980s; however, over the last few years that percentage has declined to approximately 5%. 3 Furthermore, the typical stage D patient has less advanced and more minimal metastatic disease in the late 1990s. 4 Even though this stage migration has placed more emphasis on curative therapies such as radical prostatectomy and radiation, there are still many men who are treated with primary hormonal therapy for advanced (or localized) prostate cancer. Hormonal therapy is the mainstay of treatment for advanced disease; however, controversies such as the value of combined hormonal therapy (CHT) compared to lutenizing hormone releasing hormone (LHRH) agents or orchiectomy alone remain hotly contested. 5 Additionally, the survival and outcome statistics for these less advanced, stage-migrated, or 'minimal' stage D patients is unclear. Specifically, the oft quoted mean survival of 24 months for patients with metastatic prostate cancer may not be appropriate for many men in the late 1990s. Furthermore, the racial disparity of lower survival in African-American (AA) men with prostate cancer is unclear for advanced disease. Specifically, Optenberg et al have reported that AA military beneficiaries with metastatic prostate cancer actually have better survival than similar staged and treated white men. 6 Conversely, Thompson et al recently reported that AA men with staged and treated D2 disease had poorer outcomes than similarly staged and treated white men. 7 Finally, some men choose primary hormonal therapy alone as their treatment for localized prostate cancer and the value of this approach is unclear.
This study analyzes the response to primary hormone therapy of 135 men who were diagnosed with advanced prostate cancer at the time of initial diagnosis at a tertiary care Army Medical Center. It is an attempt to better understand the use of hormonal therapy in the face of the PSA test coming into widespread use and the stage migration that occurred in the early 1990s. None were treated with primary surgery or radiation therapy. Response to therapy was reflected in PSA changes following onset of treatment. Death from prostate cancer is also evaluated and discussed.
Materials and methods
This is a consecutive, non-randomized, series of 135 prostate cancer patients who were diagnosed in the PSA era, between January 1989 and December 1995 and treated within 6 months of diagnosis by orchiectomy or LHRH therapy with or without anti-androgens. Sixty-seven patients were treated by orchiectomy, 43 of whom (64.2%) also received continuous, oral, non-steroidal anti-androgen therapy. Sixty-eight patients were treated by LHRH, 53 of whom (77.9%) also received anti-androgen therapy. Treatment was chosen as a decision between physician and patient. There was no intermittent therapy. None of the patients received primary surgery or radiation therapy. Sixty-four patients (47.4%) died during the follow-up period; all of the living patients were followed for at least 1 y except for one patient who was lost to follow-up 3 months after treatment. The mean (median) follow-up time was 31.2 (25.0) months.
Disease progression was defined as a PSA level increasing on at least two measures after a nadir had been reached. Time to disease progression was measured from the beginning of hormonal treatment to the time of the second elevated PSA. In Kaplan-Meier and Cox regression analyses of time to disease progression, patients who had not progressed prior to death or last follow-up were included as censored observations. The Cox regression model was used to assess the simultaneous influence of possible predictor variables (covariates) on the time to disease progression. A backward stepwise elimination procedure was used to remove covariates from the full model if they were not significantly related to the risk of progression. The removal (or possible re-entry) of a covariate from the model was based on the likelihood ratio statistic with significance level equal to 0.10. 
Results

Of
Clinical stage
Clinical stage was known for 124 patients:
Distribution of the 104 stage D patients was as follows: D0 ¼ 9, D1 (N1) ¼ 20 and D2 (M1) ¼ 75. In PFS analysis, three stage categories were formed: B or C (21 patients), D0 or D1 (29 patients) and D2 (75 patients). Nodal or metastatic disease was based on imaging and was not biopsy proven. There were significant differences in PFS rates by clinical stage (Table 1 and Figure 1a , P ¼ 0.013). Pair-wise comparisons showed D2 patients had significantly poorer PFS rates than D0 or D1 staged patients. Stage B or C patients were not significantly different from stage D0 or D1 patients. In subsequent multivariate PFS analysis, the two stage categories, D2 and < D2 were used ( Figure 1b ).
Age
For the 135 patients, age ranged from 42 to 89 with a mean of 70.4 and a median of 71.0. PFS rates were not significantly related to age categories (Table 1 , P ¼ 0.354). Analysis of age as a continuous variable showed PFS rates increased insignificantly with advancing age (P ¼ 0.375).
Race
Race was known for all patients: white ¼ 96, black ¼ 37, other ¼ 1 (grouped with white patients). PFS rates were not related to race (Table 1 , P ¼ 0.656).
Pre-treatment PSA
The range was 0.3 to 6150 for 123 patients with known pre-treatment PSA levels; the mean (median) was 331.0 (52.0). Pre-treatment PSA was not significantly related to PFS rates when treated as a categorical variable (Table 1 , P ¼ 0.129). However, there was a strong relationship of poorer PFS rates with increasing value of log transformed pre-treatment PSA values (P ¼ 0.004).
Alkaline phosphatase
Pre-treatment alkaline phosphatase levels were known for 93 patients: range 41 to 2347 U/l, mean ¼ 179.6 U/l, median ¼ 101.0 U/l. A cut-off level of twice the upper limit of normal was found to have the greatest correlation with survival in a study by Smith et al. 9 Using this information, three categories were formed using cut-off points of 126 U/l, which is the upper limit of normal range, and 252, which is twice the upper limit; ¼ 126 ¼ 58 (62.4%), 127 -252 ¼ 22 (23.7) and > 252 ¼ 13 (14.0%). PFS rates were significantly related to alkaline phosphatase levels (Table 1 and Figure 2a , P < 0.001). Pair-wise comparisons showed patients with alkaline phosphatase levels > 252 had significantly poorer PFS rates than those with levels < 252 or 127 -252 but these latter groups were not significantly different. In subsequent multivariable analysis, only two alkaline phosphatase categories, 252 and > 252 were used (Figure 2b ).
Type of treatment
Almost equal numbers of patients were treated by orchiectomy (67) as by LHRH (68). Four treatment categories were used in PFS analyses: orchiectomy plus anti-androgen ¼ 43 (31.9%), orchiectomy only ¼ 24 (17.8%), LHRH plus anti-androgen ¼ 53 (39.3%) and LHRH only ¼ 15 (11.1%). Type of treatment was not significantly related to PFS. (Table 1 , P ¼ 0.208). PFS analyses were also performed for 39 monotherapy patients (orchiectomy or LHRH alone) and 97 combined hormone therapy (CHT) patients (orchiectomy plus AA or LHRH plus AA). These groups were not significantly different for PFS (Table 1 , P ¼ 0.740). However, the hazard rates for those two treatment groups are not proportional; the survival curve for CHT patients is inferior to that for monotherapy patients during the first 2 y of treatment but is better than for monotherapy patients at 3 y of treatment.
Nadir PSA Nadir PSA ranged from < 0.1 to 53.4 for 115 patients whose PSA reached a nadir during follow-up. The mean (median) was 3.8 (0.2). The distribution of patients who had a nadir was < 0.1 ¼ 46 (40.0%), 0.1 -0.5 ¼ 29 (25.2%), (Table 1 and Figure 4 , P < 0.001). The best PFS rate was for those who reached a nadir of < 0.1, and the worst was for those whose nadir was > 2.0. Pair-wise comparisons showed all groups were significantly different from each other except for 0.1 -0.5 and 0.6 -2.0. In subsequent multivariate analyses, three categories for nadir PSA were used: < 0.1, 0.1 -2.0 and > 2.0. Time (in months) from the start of treatment to nadir ranged from 0.8 to 71.6, mean 11.2, median 8.4. Time from nadir to progression ranged from 0.3 to 34.7 months, mean ¼ 7.9, median ¼ 5.6.
Multivariate analysis
We first examined the simultaneous influence of five covariates (type of treatment, age, race, clinical stage, and pre-treatment PSA) on time to progression by PSA. In this analysis, age and pre-treatment PSA were entered into the Cox regression model as continuous variables (with pre-treatment PSA log transformed); the other covariables were entered as categorical variables as specified earlier. All five covariates were known for 114 patients. Using backward elimination to delete non-significant covariates from the full model, type of treatment was eliminated first (P ¼ 0.565), followed by race (P ¼ 0.339) and age (P ¼ 0.317). Clinical stage (P ¼ 0.049) and pre-treatment PSA (P ¼ 0.038) remained in the final model.
We next examined the simultaneous influence of clinical stage, pre-treatment PSA, nadir PSA and alkaline phosphatase on time to progression in 80 patients for whom all four covariates were known. Using backward elimination, clinical stage (P ¼ 0.794) and pre-treatment PSA (P ¼ 0.472) were removed; alkaline phosphatase (P ¼ 0.010) and nadir PSA (P < 0.001) remained in the full model. The relative risk of progression was 3.2 times higher for patients with an alkaline phosphatase > 252 compared to those with levels 252. The relative risk was 3.6 times greater for patients with a nadir of 0.1 -2.0 and 16.5 times greater for patients with a nadir > 2.0 compared to those with a nadir of < 0.1. 
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Death from prostate cancer
There were 36 prostate cancer deaths among the 135 patients: the 5-y disease specific survival rate was 59.2%. When CHT and monotherapy patients are compared, their disease-specific survival rates are not significantly different (Figure 1 ). Clinical stage, alkaline phosphatase, pre-treatment PSA and nadir PSA were significant predictors of survival in univariate analyses. The simultaneous influence of five covariates (type of treatment, age, race, clinical stage and pre-treatment PSA) on time to death from prostate cancer was examined using Cox regression. Variables were modeled as in the disease progression analysis except that type of treatment was CHT or monotherapy. (Collapsed into two levels, orchiectomy ( þ /7 antiandrogens) and LHRH ( þ /7 anti-androgens).) Using backward elimination to remove non-significant covariates from the full model, race was eliminated first (P ¼ 0.997), followed by type of treatment (P ¼ 0.573) and age (P ¼ 0.235). Only pre-treatment PSA (P ¼ 0.016) and clinical stage (P ¼ 0.001) remained in the final model. A Cox regression model with pre-treatment PSA, clinical stage, alkaline phosphatase and nadir PSA was also analyzed. Nadir PSA was collapsed into two levels, 2.0 and > 2.0. Using backward elimination, alkaline phosphatase (P ¼ 0.869) and pre-treatment PSA (P ¼ 0.282) were removed while clinical stage (P ¼ 0.001) and nadir PSA (P ¼ 0.001) remained in the final model.
Discussion
This study documents a tertiary hospital experience with advanced prostate cancer and primary hormonal therapy in the PSA era (1989 -1995) . Perhaps the most noteworthy finding is that survival for clinical stage D2 disease patients in the PSA era is higher than historical series. The 5-y progression free survival is 25% and 5-y disease specific survival is almost 50% (46.6%). A meta-analysis in stage D2 disease of 1980s and early 1990s patients reviewed 22 trials of castration vs combined hormonal therapy. Crude mortality rates were similar between the two methods (58 and 56%, respectively). Life table estimates of the corresponding 5-year survival rates were 22.8 and 26.2%. 9 This improvement in 5-y survival possibly reflects a migration to less extensive metastatic disease, although the exact cause is unknown.
Aside from the overall improvement in survival rates, this study does not support the concept that race or ethnicity is a prognostic factor for men with advanced prostate cancer. Although a prior Surveillance, Epidemiology and End Results (SEER) study from Detroit suggested that AA men with advanced cancer had poorer disease-specific survival than stage matched white men, 10 Optenberg et al has found no racial difference in survival for advanced prostate cancer in a large military experience. 6 However, Thompson et al recently analyzed 1387 patients enrolled in a multi-center trial of orchiectomy alone vs orchiectomy plus flutamide for stage D2 disease finding worse disease-specific survival for AA men. 7 Considering the small size of our study, we cannot provide definitive data on the issue of race as a prognostic factor in advanced prostate cancer.
In univariate analysis, baseline alkaline phosphatase and PSA nadir were significant factors relating to progression by PSA. These prognostic factors were also found to be significant in a large study by Smith et al. 8 Pre-treatment alkaline phosphatase levels were significant prognostic factors for both progression-free survival and overall survival
In our study, we found that a PSA which dropped to 2.0 was associated with an improved PFS compared to > 2.0. An even better outcome was noted in those patients whose PSA nadir was < 0.1. This observation is likely due to clonal populations of non-responsive prostate cancer cells that do not enter apoptosis and continue to thrive and produce PSA. Those men whose PSA does not nadir below 2.0 after hormone therapy could potentially benefit from therapies directed at hormone refractory cancer before their cancer shows definite progression by PSA. Further study of PSA nadir as a prognostic factor and as a trigger for therapy is needed. Figure 4 Progression-free survival rates by nadir PSA. Prostate cancer progression-free survival Kaplan-Meier analysis of 115 patients treated by primary hormonal therapy analyzed by nadir PSA value: < 0.1, 0.1 -0.5, 0.6 -2.0, > 2.0 ng/ml. Pair-wise comparisons showed all groups were significantly different from each other except for 0.1 and 0.5, which were grouped together.
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In multivariate analyses that included type of treatment, age, race, stage and PSA prior to treatment, stage and pre-treatment PSA both remained significant factors related to progression-free survival and time to death for those who died of prostate cancer. When stage, pretreatment PSA, nadir PSA and alkaline phosphatase were considered together, alkaline phosphatase and nadir PSA contributed to progression-free survival while stage and PSA nadir contributed to time to death from prostate cancer.
Since the early 1980s, anti-androgens have been used either with an LHRH agonist or orchiectomy in order to suppress the androgen production of the adrenals and treat advanced prostate cancer. 11 There is a continuing debate regarding the clinical value of this combined hormonal therapy. The National Cancer Institute (NCI) study 0036, 11 European Organization for Research and Treatment of Cancer (EORTC) study 30853, 12 Canadian Anandron study, 13 and Multinational Nilutamide Study 14 all showed a survival benefit of 7-15 months with combined hormonal therapy. Other studies, however, have not supported this finding. These include the NCI intergroup trial 0105 15 and a meta-analysis published in the Lancet that showed only a 2 -3 month survival benefit. 9 A second meta-analyses demonstrated a 7.3 -7.6 month survival benefit. 16 Our experience does not demonstrate significantly improved survival from prostate cancer death in CHT compared to monotherapy patients. It must be recognized, however, that our study is relatively small and is not a randomized trial.
Conclusion
This study documents an early PSA-era experience with the presentation and treatment of prostate cancer using primary hormone therapy. The 5-y survival rate for D-2 disease in our center is higher than pre-PSA-era series, which is likely due to stage migration. Clinical stage, baseline alkaline phosphatase level and PSA response after initiation of therapy (PSA nadir) were independent prognostic factors and can be used to predict response for those men presenting with metastatic prostate cancer.
